The honeymoon phase (remission) in type 1 diabetes

Diabetes Academy: Resources and Solutions

Assoc. Prof. Dr. Sorin Ioacara Medically reviewed Updated: April 12, 2026 9 min read

The "honeymoon period" in type 1 diabetes is a temporary phase that begins 1-2 weeks after diagnosis, when the pancreas starts to produce insulin again in significant amounts, sometimes enough to stop insulin treatment completely.

50%
of patients have partial remission
7–9 months
average duration
<0.5 U/kg/day
insulin requirement

What is the honeymoon period in type 1 diabetes?

The honeymoon period is a temporary phase after a diagnosis of type 1 diabetes when your pancreas still produces its own insulin [1]. Once you start insulin treatment and your blood glucose normalises, the remaining beta cells (5-20%) recover from "glucose toxicity" and start working better again. Your insulin requirement from external sources drops dramatically, often below 0.5 units/kg/day and sometimes even less [2].

It is called a "honeymoon" because it feels like a magical period when diabetes appears to have disappeared. Blood glucose levels are stable, you have no hypoglycaemia and you feel almost normal. However, like any honeymoon, it is temporary [1]. The autoimmune process continues to destroy the remaining beta cells, and after a while your insulin requirement will rise again.

How long does the honeymoon period last in type 1 diabetes?

The duration of the honeymoon period varies enormously, from a few weeks to almost 3 years, with an average of 7-9 months [3]. In young children (under 5 years) it may be completely absent or last for a shorter time, as the autoimmune process is generally more aggressive [4]. Adolescents usually have a few months of remission, while adults diagnosed with LADA can have a honeymoon period of 3 years [5].

Factors that prolong the honeymoon period include excellent glycaemic control from the start (preventing glucotoxicity), early diagnosis before ketoacidosis, older age at onset and the presence of at most one autoantibody [4]. You cannot predict the exact duration, but monitoring C-peptide and your insulin requirement can show you when you are approaching the end [6].

Why do I need less insulin now?

You need less insulin during the honeymoon period because your surviving beta cells have partially resumed their function [1]. When your blood glucose was very high before diagnosis, the beta cells were paralysed by so-called glucose toxicity. Once blood glucose is normalised with external insulin, they recover and can produce insulin again, although often not enough for complete independence [6].

In addition, your insulin sensitivity has improved in the meantime. Your body's cells now respond better both to injected insulin and to insulin produced internally [2]. It is like having temporary help that covers at least half of your insulin requirement, if not all of it. This residual production also makes control easier, with fewer blood glucose fluctuations.

Can I stop taking insulin during the honeymoon period?

Most often you cannot stop insulin completely [7]. Sometimes, if your blood glucose levels are perfect, you can do this (total remission), but with a lifestyle adapted for this situation. Stopping insulin during the honeymoon period when your blood glucose levels and lifestyle do not actually allow it accelerates the destruction of the remaining beta cells and can lead to ketoacidosis [8]. Maintaining a minimum insulin dose (0.1 units/kg/day) prolongs the honeymoon period and residual beta cell function [7].

Even if your blood glucose seems normal without insulin, the autoimmune process continues. Without external insulin, the beta cells are forced to work at maximum capacity, which attracts the immune system [8]. External insulin gives them "rest" and may have a protective effect. Reducing your insulin doses during the honeymoon period according to your needs is always a safe approach (partial remission).

How do I know when the honeymoon period is ending?

The end of the honeymoon period sets in gradually, not abruptly [6]. Early signs include an increased insulin requirement (0.5 units/kg/day), variable blood glucose that is harder to control, the reappearance of high morning blood glucose (the dawn phenomenon), the need for more frequent and larger corrections, and sometimes the appearance of ketone bodies with persistently high blood glucose [9].

C-peptide monitoring objectively confirms the end of the remission period [9]. When stimulated C-peptide falls below 0.2 nmol/L (approximately 0.6 ng/ml), residual production is clearly insufficient. It is not a personal failure when the honeymoon period ends. It is the natural, inevitable evolution of the disease. Prepare yourself psychologically and practically for the transition, inevitable at some point, to more intensive diabetes management.

Do all patients with type 1 diabetes have a honeymoon period?

No, not all patients with type 1 diabetes have a honeymoon period. However, at least half of patients experience a period of partial remission, and approximately one fifth start directly with complete insulin dependence [3]. Very young children (under 5 years) and those with onset in severe ketoacidosis have fewer chances of a honeymoon period [4]. Complete and rapid destruction of the beta cells sometimes leaves nothing to recover.

Adults and those diagnosed early, before the appearance of severe symptoms, have a higher chance of a honeymoon period [10]. The presence of residual secretory function and excellent glycaemic control from the start are positive predictors of at least partial remission. The absence of a honeymoon period does not mean a worse long-term prognosis, just the need for more intensive management from the beginning.

Can I prolong the honeymoon period?

Yes, you can influence the duration of the honeymoon period through strict glycaemic control [1]. Maintaining blood glucose between 70-140 mg/dl (3.9-7.8 mmol/L) reduces stress on the beta cells and slows destruction. Avoiding episodes of severe hyperglycaemia and ketoacidosis is crucial [8]. These accelerate the loss of residual secretory function. Good glycaemic control in the first year appears to contribute to maintaining beta cell function [11].

Regular physical exercise improves insulin sensitivity and reduces requirements, indirectly protecting the beta cells [10]. Some studies suggest that a moderate low-carb diet may help. Taking part in clinical trials of therapies that maintain beta cell function (immunomodulators) offers additional chances of prolonging the temporary remission period [7].

Why does my blood glucose fluctuate during the honeymoon period?

Blood glucose fluctuates during the honeymoon period because of the inconsistent and unpredictable production of endogenous insulin [12]. The remaining beta cells do not always work in the same way. Sometimes they produce more, other times less, depending on several factors such as stress, sleep or various infections. This variability overlaps with the insulin you may inject, creating further variability [6].

In addition, the response of the beta cells to stimuli (food) is delayed and inadequate. The remaining beta cells can sometimes release insulin when they should not, leading to unexplained hypoglycaemia [12]. At other times they seem not to respond when you need them, with hyperglycaemia appearing after a somewhat larger meal. It is frustrating, but temporary. Flexibility in choosing your insulin doses and frequent monitoring are the key to adapting to these fluctuations.

Is it normal to have partial remission?

It is absolutely normal and beneficial! Partial remission means you still have residual beta cell function, which makes management easier, although, it is true, only temporarily [2]. Partial refers to the fact that you do not stop insulin completely. It is not a cure or a sign that the diagnosis was wrong. It is part of the natural evolution of type 1 diabetes in most patients and should be made the most of for as long as it lasts [9].

The presence of a honeymoon period is associated with a better long-term prognosis [9]. The reason lies in better glycaemic control, with less variability and a lower risk of chronic complications. People who maintain detectable C-peptide even many years after diagnosis (minimal beta cell function) have less glycaemic variability and a lower risk of severe hypoglycaemia [13]. Enjoy this period, but prepare yourself realistically for what comes next.

What happens after the honeymoon period?

After the honeymoon period, you will need full doses of insulin (0.7-1.0 units/kg/day, or more during adolescence) [14]. Glycaemic control becomes more difficult, with increased variability and the need for frequent adjustments [9]. The dawn phenomenon and the dusk phenomenon (in the evening) become evident, requiring differentiated basal rates if you use an insulin pump. Your response to insulin starts to fluctuate more with the menstrual cycle, with stress or with various infections [14].

It is nothing serious, just a new stage that requires adaptation. Modern technologies (pumps, sensors, closed-loop systems) make management much easier than in the past. Most people adapt to the new normal within a few months.

Conclusions

  • The honeymoon period is a temporary phase after a type 1 diabetes diagnosis in which the surviving beta cells partially resume function, reducing the external insulin requirement often below 0.5 units/kg/day [1] [2].
  • Remission duration varies from a few weeks to about 3 years (on average 7–9 months), being shorter in young children and longer in adults diagnosed with LADA [3] [5].
  • External insulin should not be stopped completely during this period; maintaining even a minimum dose protects the remaining beta cells and may prolong the duration of remission [7] [8].
  • The end of the honeymoon period is recognised by a gradual rise in the insulin requirement and is objectively confirmed when stimulated C-peptide falls below 0.2 nmol/L [6] [9].
  • The presence of partial remission is associated with a favourable long-term prognosis, with less glycaemic variability and a reduced risk of severe hypoglycaemia and chronic complications [9] [13].

You might also be interested in:

Other pages available in the type 1 diabetes diagnosis and staging domain

References

  1. Collier JJ, Wasserfall CH, Brehm MA, Karlstad MD. Partial remission of type 1 diabetes: Do immunometabolic events define the honeymoon period? Diabetes Obes Metab. 2025;27(8):4092-4101. PubMed
  2. Zhong T, Tang R, Gong S, Li J, Li X, Zhou Z. The remission phase in type 1 diabetes: Changing epidemiology, definitions, and emerging immuno-metabolic mechanisms. Diabetes Metab Res Rev. 2020;36(2):e3207. PubMed
  3. Abdul-Rasoul M, Habib H, Al-Khouly M. 'The honeymoon phase' in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes. 2006;7(2):101-107. PubMed
  4. Lombardo F, Valenzise M, Wasniewska M, Messina MF, Ruggeri C, Arrigo T, De Luca F. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr Metab. 2002;15(4):246-251. PubMed
  5. Marcon LMR, Fanelli CG, Calafiore R. Type 1 Diabetes (T1D) and Latent Autoimmune Diabetes in Adults (LADA): The Difference Between a Honeymoon and a Holiday. Case Rep Endocrinol. 2022;2022:9363543. PubMed
  6. Nwosu BU. Partial Clinical Remission of Type 1 Diabetes Mellitus in Children: Clinical Applications and Challenges with its Definitions. EMJ Diabetes. 2019;4(1):89-98. PubMed
  7. Jacobsen LM, Bundy BN, Greco MN, Schatz DA, Atkinson MA, Brusko TM, Mathews CE, Herold KC, Gitelman SE, Krischer JP, Haller MJ. Comparing Beta Cell Preservation Across Clinical Trials in Recent-Onset Type 1 Diabetes. Diabetes Technol Ther. 2020;22(12):948-953. PubMed
  8. Mittal M, Porchezhian P, Kapoor N. Honeymoon phase in type 1 diabetes mellitus: A window of opportunity for diabetes reversal? World J Clin Cases. 2024;12(1):9-14. PubMed
  9. Jeyam A, Colhoun H, McGurnaghan S, Blackbourn L, McDonald TJ, Palmer CNA, et al.; SDRNT1BIO Investigators. Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care. 2021;44(2):390-398. PubMed
  10. Sokołowska M, Chobot A, Jarosz-Chobot P. The honeymoon phase - what we know today about the factors that can modulate the remission period in type 1 diabetes. Pediatr Endocrinol Diabetes Metab. 2016;22(2):66-70. PubMed
  11. Nwosu BU. Guidance for high-dose vitamin D supplementation for prolonging the honeymoon phase in children and adolescents with new-onset type 1 diabetes. Front Endocrinol (Lausanne). 2022;13:974196. PubMed
  12. Gomez-Muñoz L, Dominguez-Bendala J, Pastori RL, Vives-Pi M. Immunometabolic biomarkers for partial remission in type 1 diabetes mellitus. Trends Endocrinol Metab. 2024;35(2):151-163. PubMed
  13. Gubitosi-Klug RA, Braffett BH, Hitt S, Arends V, Uschner D, Jones K, et al.; DCCT/EDIC Research Group. Residual β cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. J Clin Invest. 2021;131(3):e143011. PubMed
  14. Silver B, Ramaiya K, Andrew SB, Fredrick O, Bajaj S, Kalra S, Charlotte BM, Claudine K, Makhoba A. EADSG Guidelines: Insulin Therapy in Diabetes. Diabetes Ther. 2018;9(2):449-492. PubMed